Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian Imatinib-Resistant patients with chronic myeloid leukemia
F Tadesse, G Asres, A Abubeker… - JCO global …, 2021 - ascopubs.org
PURPOSE Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
[PDF][PDF] Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
MD Fisihatsion Tadesse, MD Getahun Asres… - pdfs.semanticscholar.org
RESULTS A total of 962 cases of CML on imatinib therapy were reviewed and 164 cases of
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
[PDF][PDF] Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
MD Fisihatsion Tadesse, MD Getahun Asres… - 2021 - academia.edu
RESULTS A total of 962 cases of CML on imatinib therapy were reviewed and 164 cases of
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
F Tadesse, G Asres, A Abubeker… - JCO Global …, 2021 - europepmc.org
Purpose Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
F Tadesse, G Asres, A Abubeker… - JCO global …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
[PDF][PDF] Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
MD Fisihatsion Tadesse, MD Getahun Asres… - 2021 - researchgate.net
RESULTS A total of 962 cases of CML on imatinib therapy were reviewed and 164 cases of
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
[HTML][HTML] Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
F Tadesse, G Asres, A Abubeker… - JCO Global …, 2021 - ncbi.nlm.nih.gov
PURPOSE Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …
[PDF][PDF] Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
MD Fisihatsion Tadesse, MD Getahun Asres… - 2021 - researchgate.net
RESULTS A total of 962 cases of CML on imatinib therapy were reviewed and 164 cases of
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …
failure were found. Of these, only 31 cases (19%) had mutation analysis performed. Most …